Advertisement

Topics

Search Results for "Takeda"

13:28 EDT 27th September 2016 | BioPortfolio

Original Source: Takeda to cease distribution of Pfizer’s Prevenar 13 and BeneFIX in Japan

Takeda Pharma has concluded an agreement to cease distribution of the pneumococcus conjugate vaccine…

Matching Channels

Pertussis Vaccine acellular Takeda

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Matching News

Figure: Tracking Takeda

Taking Takeda global Tracking Takeda Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) wants to maintain its position in the top 10 cancer companies and become the number one GI company in the next five to ...

Teva and Takeda establish ‘Teva Takeda Yakuhin’ in Japan

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Japan-based Takeda Pharmaceutical Company (Takeda) have formed a joint company ‘Teva Takeda Yakuhin’ to produce and sell off-patent...

Takeda's Brintellix Renamed Trintellix

​Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively “Takeda”), and Lundbeck announced that Brintellix(vortioxetine) ...

Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders / Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroent

DUBLIN, IRELAND and OSAKA, JAPAN -- (Marketwired) -- 06/08/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda")...

Takeda and Teva Establish "Teva Takeda Yakuhin Ltd." in Japan

http://www.takeda.com/news/2015/20151228_7258.html

Takeda, PRA Health Sciences ink agreement

PRA Health Sciences and Takeda Pharmaceutical have entered into a new partnership agreement under which PRA Health Sciences will serve as Takeda’s primary strategic partner to deliver on the company...

Takeda Initiates World's First Norovirus Vaccine Field Trial

Osaka, Japan, June 20, 2016 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that it has dosed the first subject in a Phase 2b field efficacy trial of ...

Takeda to Study Prosetta Biosciences' CNS Compounds

Takeda Pharmaceutical will partner with Prosetta Biosciences on a feasibility study for possible future co-development of Prosetta’s novel compounds for central nervous system diseases and dis...

Matching PubMed Articles

Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.

This article discusses the impact of bile acid sequestrants (BAS) on cardiovascular risk factors (CVRFs), on the basis of recent (pre)clinical studies assessing the metabolic impact of modulation of e...

Efficacy of Human Fibrinogen-Thrombin Patch (TachoSil) Clinical Application in Upper Gastrointestinal Cancer Surgery.

Previous studies investigated the efficacy and applicability of tissue adhesives in gastrointestinal surgery while no evidence is available to date about a novel compound, TachoSil (Takeda, Zurich, Sw...

Efficacy and safety of human fibrinogen-thrombin patch (Tachosil(®)) in the management of diffuse bleeding after chest wall and spinal surgical resection for aggressive thoracic neoplasms.

Diffuse bleeding after chest wall and spine resection represents a major problem in General Thoracic Surgery. Several fibrin sealants (FS) have been developed over the years and their use has been gra...

Vaccines against norovirus: state of the art trials in children and adults.

Noroviruses (NoVs), a group of nonenveloped, single-stranded RNA viruses belonging to the Caliciviridae family, are the leading cause worldwide of acute infectious gastroenteritis. Serious and eventua...

Inhibition of Phosphoinositide 3-Kinase (PI3K) promotes dilation of human small airways in a Rho kinase-dependent manner.

Asthma manifests as a heterogeneous syndrome characterized by airway obstruction, inflammation and hyperresponsiveness (AHR). Although the molecular mechanisms remain unclear, activation of specific p...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement